Avalo Therapeutics price to sales ratio AVTX

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 5.0×; May 2024
8-year median: 8.0×
8-year range: 0.1× to 79.3×
Peer median: 1.5×

Avalo Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2024, at 5.0×.

On the days it had one over the last 8 years, its median was 8.0×, from 0.1× in Sep 2023 to 79.3× in Jun 2021.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	5.0×	1.5×	7.7×
2023	3.2×	0.1×	7.7×
2022	2.7×	2.7×	18.2×
2021	28.6×	28.6×	79.3×
2020	6.5×	6.1×	10.8×
2019	11.1×	6.4×	16.2×
2018	8.2×	3.6×	9.8×

Against its peers

Companies in Drug Manufacturers - General nearest Avalo Therapeutics' size, closest first, today.

Company	Price to sales ratio
AVTXAvalo Therapeutics	n/m
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
NATRNatures Sunshine Products	0.4×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Avalo Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.